Accelerating Heart Disease Research: Allen Institute’s New Disease-Specific Cell Lines
On June 4, 2024, the Allen Institute for Cell Science announced the launch of its first disease-specific cell line collections, marking a significant milestone in genetic heart disease research. This innovative set of tools, specifically designed to advance the study of hypertrophic cardiomyopathy (HCM) and other muscle disorders, represents a groundbreaking step in the quest […]
REPROCELL USA Launches Advanced GMP Facility for Stem Cell Manufacturing
REPROCELL USA has marked a significant milestone with the inauguration of its state-of-the-art GMP manufacturing facility dedicated to producing high-quality stem cells. This facility, located in Beltsville, Maryland, was officially opened on May 15, 2024, by Mr. Kevin Anderson, Secretary of the Department of Commerce, State of Maryland. The new facility is designed to manufacture […]
StemBioSys Announces Launch of NeuroMatrix™, a Technological Leap Forward in Laboratory Production of Functionally Mature Human Neural Cell Types
SAN ANTONIO, Feb. 13, 2023 /PRNewswire/ — StemBioSys, Inc. (StemBioSys) announced today the launch of NeuroMatrix™, an astrocyte-derived extracellular matrix that enables the culture of human induced pluripotent stem cell (hiPSC) derived and primary neural cell types. StemBioSys designed NeuroMatrix™ to expand the use of iPSC-derived neurons in drug discovery and toxicity testing. “NeuroMatrix™ represents a breakthrough in hiPSC-derived neuronal development […]
Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Vast Potential in Cell Therapy, Disease Modelling, Drug Development and Discovery, Personalized Medicine & Toxicology Testing
DUBLIN, July 13, 2022 /PRNewswire/ — The “Global Induced Pluripotent Stem Cell (iPSC) Industry Report, 2022” report has been added to ResearchAndMarkets.com’s offering. Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new […]
Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Dementia with Lewy Bodies
NEW YORK, June 9, 2022 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced data demonstrating a statistically significant (p<0.01) 19% downregulation of mRNA and a ~40% reduction of alpha synuclein (α-synuclein) in an in vitro study […]